These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 41413)

  • 1. Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial.
    Magelund G; Gerlach J; Casey DE
    Acta Psychiatr Scand; 1979 Aug; 60(2):185-9. PubMed ID: 41413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic-potentiating effect of metyrosine.
    Magelund G; Gerlach J; Casey DE
    Am J Psychiatry; 1979 May; 136(5):732. PubMed ID: 35016
    [No Abstract]   [Full Text] [Related]  

  • 3. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.
    Ruskin PE; Nyman G
    J Nerv Ment Dis; 1991 Apr; 179(4):212-4. PubMed ID: 1672547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients.
    Bechelli LP; Ruffino-Netto A; Hetem G
    Braz J Med Biol Res; 1983 Dec; 16(4):305-11. PubMed ID: 6143579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
    Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
    Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine.
    Nasrallah HA; Donnelly EF; Bigelow LB; Rivera-Calimlim L; Rogol A; Potkin S; Rauscher FP; Wyatt RJ
    Arch Gen Psychiatry; 1977 Jun; 34(6):649-55. PubMed ID: 17374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
    Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
    Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carotid body dopamine content and release by short-term hypoxia: effect of haloperidol and alpha methyl paratyrosine.
    Basson H; Bairam A; Cottet-Emard JM; Pequignot JM; Marchal F
    Arch Physiol Biochem; 1997 Feb; 105(1):3-9. PubMed ID: 9224540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone: clinical safety and efficacy in schizophrenia.
    Borison RL; Pathiraja AP; Diamond BI; Meibach RC
    Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.
    Klemp M; Tvete IF; Skomedal T; Gaasemyr J; Natvig B; Aursnes I
    J Clin Psychopharmacol; 2011 Dec; 31(6):698-704. PubMed ID: 22020356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study.
    Lee HS; Song DH; Kim JH; Lee YM; Han ES; Yoo KJ
    Int Clin Psychopharmacol; 1995 Jun; 10(2):67-72. PubMed ID: 7673658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.